Provectus Pharmaceuticals Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Provectus Pharmaceuticals Inc.

PVCT 0.0725

+3.6%

Oct 31 3:52 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: boomertree2	7/15/2014 10:14:36 AM
	of 13111

Swiss Firm Says Melanoma Treatment Meets Study Goals. Reuters (7/14) reports that Roche disclosed its experimental medication, cobimetinib, being developed in collaboration with Exelixis Inc., extended the life of patients with advanced skin cancer, when used with its Zelboraf (vemurafenib) medicine, according to a Phase III study. The test met Roche’s goal of extending the life of patients without worsening their condition. The Wall Street Journal (7/14, Maclucas, Subscription Publication) notes Roche will use the results to bolster its approval case with the FDA, EMA and other regulatory bodies.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next